IDEAYA Biosciences, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
IDEAYA Biosciences, Inc. (IDYA) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$23.88 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-17
- IDEAYA Biosciences, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$23.88M.
- IDEAYA Biosciences, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$57.64M.
- IDEAYA Biosciences, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$23.72M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$23.88M 10-K · filed 2026-02-17 |
| 2024-12-31 | -$57.64M 10-K · filed 2026-02-17 |
| 2023-12-31 | -$23.72M 10-K · filed 2026-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |